Company Performance - Oncobiologics reported a quarterly loss of $0.44 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.42, but an improvement from a loss of $0.83 per share a year ago, indicating a year-over-year improvement in losses [1] - The company posted revenues of $1.51 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 40.98%, compared to zero revenues a year ago [2] - Over the last four quarters, Oncobiologics has surpassed consensus EPS estimates two times [2] Stock Performance - Oncobiologics shares have increased by approximately 12.7% since the beginning of the year, outperforming the S&P 500's gain of 10% [3] - The current Zacks Rank for Oncobiologics is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is -$0.33 on revenues of $5.78 million, and for the current fiscal year, it is -$1.89 on revenues of $6.42 million [7] - The outlook for the Medical - Biomedical and Genetics industry, in which Oncobiologics operates, is currently in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Group 1 - VYNE Therapeutics Inc. reported a quarterly loss of $0.13 per share, better than the Zacks Consensus Estimate of a loss of $0.23, representing an earnings surprise of +43.48% [1] - The company posted revenues of $0.07 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 31%, and a decline from $0.2 million in the same quarter last year [2] - VYNE Therapeutics shares have decreased by approximately 89.6% since the beginning of the year, contrasting with the S&P 500's gain of 10% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.25 on revenues of $0.15 million, and for the current fiscal year, it is -$0.94 on revenues of $0.6 million [7] - The Medical - Drugs industry, to which VYNE Therapeutics belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Company Performance - CI&T Inc. reported quarterly earnings of $0.07 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, and up from $0.03 per share a year ago, representing an earnings surprise of +16.67% [1] - The company posted revenues of $117.19 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.61%, compared to year-ago revenues of $100.45 million [2] - Over the last four quarters, CI&T has surpassed consensus revenue estimates three times [2] Stock Performance - CI&T shares have declined approximately 18.3% since the beginning of the year, while the S&P 500 has gained 9.6% [3] - The current Zacks Rank for CI&T is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is $0.07 on revenues of $123.91 million, and for the current fiscal year, it is $0.28 on revenues of $479.2 million [7] - The outlook for the Internet - Software industry, where CI&T operates, is currently in the top 32% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

分组1 - ReNew Energy Global PLC (RNW) reported quarterly earnings of $0.16 per share, exceeding the Zacks Consensus Estimate of $0.11 per share, and showing a significant improvement from break-even earnings per share a year ago, resulting in an earnings surprise of +45.45% [1] - The company achieved revenues of $480 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 16.90%, and compared to year-ago revenues of $299 million, indicating strong revenue growth [2] - ReNew Energy Global shares have increased approximately 10.1% since the beginning of the year, outperforming the S&P 500's gain of 9.6% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.22 on revenues of $465.9 million, and for the current fiscal year, it is $0.26 on revenues of $1.59 billion [7] - The Alternative Energy - Other industry, to which ReNew Energy Global belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Core Insights - Red Robin (RRGB) reported quarterly earnings of $0.26 per share, exceeding the Zacks Consensus Estimate of a loss of $0.25 per share, and showing improvement from a loss of $0.48 per share a year ago, resulting in an earnings surprise of +204.00% [1] - The company posted revenues of $283.7 million for the quarter ended June 2025, which was a miss against the Zacks Consensus Estimate by 0.53%, and a decline from year-ago revenues of $300.15 million [2] - Red Robin shares have increased by approximately 12.2% since the beginning of the year, outperforming the S&P 500's gain of 9.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.78 on revenues of $265.2 million, and for the current fiscal year, it is -$1.12 on revenues of $1.22 billion [7] - The estimate revisions trend for Red Robin was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Industry Context - The Retail - Restaurants industry, to which Red Robin belongs, is currently ranked in the bottom 25% of over 250 Zacks industries, suggesting that the outlook for the industry can significantly impact stock performance [8]

Core Insights - Xos, Inc. reported a quarterly loss of $0.91 per share, better than the Zacks Consensus Estimate of a loss of $1.06, and an improvement from a loss of $1.23 per share a year ago, resulting in an earnings surprise of +14.15% [1] - The company generated revenues of $18.39 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 40.51%, compared to $15.53 million in the same quarter last year [2] - Xos shares have increased approximately 4% year-to-date, while the S&P 500 has gained 9.6% [3] Earnings Outlook - The future performance of Xos stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is -$0.94 on revenues of $18.04 million, and for the current fiscal year, it is -$4.10 on revenues of $56.21 million [7] Industry Context - The Automotive - Domestic industry, to which Xos belongs, is currently ranked in the bottom 27% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Viewpoint - Thryv Holdings, Inc. (THRY) is positioned as a strong investment opportunity due to its improving earnings outlook and rising analyst estimates [1][2]. Earnings Estimate Revisions - Analysts have shown growing optimism regarding Thryv's earnings prospects, leading to a trend in estimate revisions that is expected to positively impact the stock price [2]. - The earnings estimate for the current quarter is $0.43 per share, reflecting a significant increase of +116.2% compared to the previous year [5]. - For the full year, the earnings estimate stands at $1.38 per share, indicating a remarkable change of +169.0% from the year-ago figure [6]. - Over the past month, the consensus estimate for the current year has increased by 26.98% due to one upward revision and no negative revisions [6][7]. Zacks Rank and Performance - Thryv currently holds a Zacks Rank 2 (Buy), which is indicative of promising estimate revisions and suggests potential for outperformance [8]. - Historically, stocks with a Zacks Rank 1 (Strong Buy) and 2 (Buy) have significantly outperformed the S&P 500 [8]. Stock Performance - The stock has gained 13.6% over the past four weeks, driven by solid estimate revisions and positive earnings growth prospects [9].

Group 1 - Potbelly (PBPB) shares have increased by 1.2% over the past four weeks, closing at $12.85, with a mean price target of $17.33 indicating a potential upside of 34.9% [1] - The mean estimate includes three short-term price targets with a standard deviation of $3.06, where the lowest estimate of $14.00 suggests a 9% increase, and the highest estimate of $20.00 indicates a 55.6% surge [2] - Analysts show strong agreement on PBPB's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for PBPB has risen by 13% over the past month, with no negative revisions, indicating positive earnings prospects [12] - PBPB holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13] - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [14]

Company Performance - Lucid Diagnostics Inc. reported a quarterly loss of $0.1 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, representing an earnings surprise of -11.11% [1] - The company posted revenues of $1.16 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 29.22%, compared to revenues of $0.98 million a year ago [2] - Over the last four quarters, Lucid Diagnostics has not surpassed consensus EPS estimates, but it has topped consensus revenue estimates twice [2] Stock Movement and Outlook - Lucid Diagnostics shares have increased approximately 21.8% since the beginning of the year, outperforming the S&P 500's gain of 9.6% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$0.09 on $1 million in revenues, and for the current fiscal year, it is -$0.41 on $5 million in revenues [7] Industry Context - The Medical - Instruments industry, to which Lucid Diagnostics belongs, is currently ranked in the bottom 39% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Lucid Diagnostics' stock performance [5]

Core Insights - Meritage Hospitality Group Inc. reported a quarterly loss of $0.04 per share, significantly missing the Zacks Consensus Estimate of $0.54, and down from earnings of $0.33 per share a year ago, resulting in an earnings surprise of -107.41% [1] - The company posted revenues of $163.53 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 9.65% and down from $172.36 million year-over-year [2] - The stock has underperformed the market, losing about 14.3% since the beginning of the year compared to the S&P 500's gain of 8.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.46 on revenues of $173.1 million, and for the current fiscal year, it is $0.98 on revenues of $685.8 million [7] - The estimate revisions trend for Meritage Hospitality Group was unfavorable ahead of the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Retail - Restaurants industry, to which Meritage Hospitality Group belongs, is currently in the bottom 24% of over 250 Zacks industries, suggesting a challenging environment for the stock [8] - Another company in the same industry, Dave & Buster's, is expected to report quarterly earnings of $0.90 per share, reflecting a year-over-year decline of 19.6% [9]